Metabolic Reprogramming by Dual AKT/ERK Inhibition Through Imipridones Elicits Unique Vulnerabilities in Glioblastoma

PURPOSE: The goal of this study is to enhance the efficacy of imipridones, a novel class of AKT/ERK inhibitors that displayed limited therapeutic efficacy against glioblastoma. EXPERIMENTAL DESIGN: Gene set enrichment, LC/MS and extracellular flux analysis were used to determine the mechanism of act...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Ishida, Chiaki T., Zhang, Yiru, Bianchetti, Elena, Shu, Chang, Trang, Nguyen T. T., Kleiner, Giulio, Sanchez-Quintero, Maria J., Quinzii, Catarina M., Westhoff, Mike-Andrew, Karpel-Massler, Georg, Prabhu, Varun V., Allen, Joshua E., Siegelin, Markus D.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6214769/
https://ncbi.nlm.nih.gov/pubmed/30037819
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-1040
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky